# Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

> **NCT00390884** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 173 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Virus Vaccine, Fluzone®
- **BIOLOGICAL:** Influenza Virus Vaccine, Fluzone®

## Key facts

- **NCT ID:** NCT00390884
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-06
- **Final completion:** 2008-09
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00390884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00390884, "Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00390884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*